While many treatments focus on easing pain for the short term, a new study suggests that a drug already in use for other purposes might help treat one of the root causes of lower back pain—especially ...

AbbVie's BCL-2 inhibitor navitoclax has reported phase 2 results in a trial involving rare and hard-to-treat blood cancer myelofibrosis, eyeing an indication not addressed with Venclexta ...

Lower back pain is something most people will deal with at some point—around 8 out of 10 people, in fact. It can be mild or ...